solu-cortef 100 mg injekció
pfizer kft. - hidrokortizon -
cortef 5 mg tabletta
pharmacia kft. - hidrokortizon -
cortef 10 mg tabletta
pharmacia kft. - hidrokortizon -
cortotic 0,584 mg/ml oldatos fülspray, kutyák számára
virbac - hidrokortizon-aceponát - oldatos fülspray - hydrocortisone - kutya
aspirin ultra 500 mg bevont tabletta
bayer hungária kft. - acetilszalicilsav -
dobutamin admeda 250 mg oldatos infúzió
admeda arzneimittel gmbh - dobutamin -
dobutamin hexal 250 mg por oldatos infúzióhoz
sandoz hungária kft. - dobutamin -
sunlenca
gilead sciences ireland unlimited company - lenacapavir sodium - hiv fertőzések - vírusellenes szerek szisztémás alkalmazásra - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 és 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 és 5.
fortum 250 mg injekció
glaxosmithkline kft. - ceftazidime -
protopic
leo pharma a/s - takrolimusz - dermatitis, atopic - egyéb bőrgyógyászati készítmények - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. előforduló négy vagy több alkalommal évente), akik már az első reakció, hogy legfeljebb hat héttel a kezelés naponta kétszer takrolimusz tartalmú (elváltozások tiszta, majdnem tiszta vagy enyhén érintett).